Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

34.61USD
20 Aug 2019
Change (% chg)

$-0.57 (-1.62%)
Prev Close
$35.18
Open
$35.12
Day's High
$35.16
Day's Low
$34.58
Volume
5,156,102
Avg. Vol
6,685,484
52-wk High
$46.46
52-wk Low
$33.97

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH)... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  PFE.N Industry Sector
P/E (TTM): 26.26 29.89 32.67
EPS (TTM): 1.37 -- --
ROI: 6.00 14.89 14.48
ROE: 13.80 16.01 15.78

Eli Lilly wins Fed Circuit decision fending off generic Alimta

Eli Lilly and Company won a federal appeals court decision on Friday that protects its chemotherapy drug Alimta from generic competition from Pfizer Inc and Dr Reddy's Laboratories Ltd.

Aug 09 2019

Merck KGaA's profit bolstered by lab supplies, drug milestone payments

FRANKFURT Germany's Merck KGaA posted a gain in quarterly earnings that was slightly higher than market expectations thanks to strong sales growth at its lab supplies unit and milestone payments from drug development partners.

Aug 08 2019

UPDATE 1-Merck KGaA's profit bolstered by lab supplies, drug milestone payments

* Life Science unit boosted by demand for lab supplies and gear

Aug 08 2019

Merck KGaA's Q2 profit bolstered by drug milestone payments

FRANKFURT, Aug 8 Germany's Merck KGaA posted a gain in quarterly earnings that was slightly higher than market expectations, driven by drug development milestone payments from partners Pfizer and GlaxoSmithKline .

Aug 08 2019

Case to Watch: NLRB to decide if gag clause in Pfizer's arbitration agreements is legal

Pfizer Inc is urging the National Labor Relations Board to rule that a U.S. Supreme Court decision that said class-action waivers in employee arbitration agreements do not violate workers' rights to organize also applies to confidentiality clauses in the pacts.

Aug 06 2019

RPT-GRAPHIC-Mylan stock boost follows long share struggles for company, generics industry

NEW YORK, July 29 Shares of Mylan NV surged on Monday after the generic drugmaker agreed to combine with Pfizer Inc's off-patent branded drugs business. But in the bigger picture, the surge is lost in a bleaker landscape for Mylan's stock price and the broader generic drug industry since 2015.

Jul 30 2019

PRESS DIGEST- New York Times business news - July 30

July 30 The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.

Jul 30 2019

UPDATE 2-J&J says FTC probing efforts to protect arthritis drug Remicade

WASHINGTON, July 29 The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

Jul 29 2019

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Jul 29 2019

UPDATE 2-Mylan deal puts future of its beleaguered EpiPen in spotlight

July 29 Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Jul 29 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates